Authors


Raoul S. Concepcion, MD, FACS

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.



Leland Chung, PhD

Latest:

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.



Brett L. Ecker, MD

Latest:

The Effect of Multidisciplinary Teams for Advancing Research in NETs

Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.


Xianyan Chen, MD

Latest:

Survival of Patients With Inoperable Non–Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation Pneumonitis

Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.



A. Gabriella Wernicke, MD, MSc

Latest:

ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating

A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.


Joanna L. Langner, MS

Latest:

Evaluation and Management of Testicular Cancer After Late Relapse

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.


Seth Felder, MD

Latest:

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.




Russ Conroy

Latest:

Novel Vaccine Shows Early Responses in Pancreatic Cancer and CRC

Phase 1 data may support continued research of amphiphile lymph node-targeted immunotherapy in solid tumors.



Caroline Seymour

Latest:

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.



Hannah Clarke

Latest:

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.


Elizabeth Maher, MD, PhD

Latest:

Recent Research and Future Directions in IDH-Mutant Gliomas

Panelists discuss how voracidinib shows superior brain penetration compared to other IDH inhibitors and explore exciting combination approaches with immunotherapy and vaccines that target the immunosuppressive effects of 2-HG in the tumor microenvironment.


Shebli Atrash, MD

Latest:

Finding the Best Setting for Bispecific T-Cell Engagers in Multiple Myeloma

Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.




Lisa Adams, PA-C

Latest:

Advanced Bladder Cancer: Future Directions in Care

Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.


Meletios A. Dimopoulos, MD

Latest:

Meletios A. Dimopoulos, MD, on the Future of a Combination Therapy in Multiple Myeloma

Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma.




Maria Bromberg, MPH

Latest:

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.



Hideaki Bando, MD

Latest:

Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies

Circulating tumor DNA (ctDNA)-based next- generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. The existence of various companion trials for common alterations that can be potential therapy targets on the 2 platforms can lead to future international collaboration.



Lauren M. Perry, MD, MAS

Latest:

Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A Review

This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.